brain specific proteins
Recently Published Documents


TOTAL DOCUMENTS

71
(FIVE YEARS 0)

H-INDEX

21
(FIVE YEARS 0)

Author(s):  
Mahmood Noorishadkam ◽  
Shekoofeh Savabieh ◽  
Mohammad Emad Sharifi

Biomarkers are particles that are released from target organs during tissue hypoxia injury. Recognizing biomarkers released from the damaged brain helps physicians determine the extent of tissue damage and the use of protective techniques in clinical treatment.  Previous studies revealed that biomarkers such as brain-specific proteins (neuron-specific enolase (NSE), S100B, ubiquitincarboxy-terminal hydrolase-L1, total Tau) and cytokines, including IL-6, IL-1β, IL-10, IL-13, interferon-gamma, TNF alpha and brain-derived neurotrophic factor are useful in diagnosing hypoxic-ischemic encephalopathy (HIE) and predicting nerve growth outcomes. However, optimal sensitivity and specificity of these biomarkers have not been achieved, which has limited their clinical application. This review focuses on biomarkers such as lactate, LDH, NRBC, NSE, S100B, GFAP, CPK-BB, IL-6, NPBI, UCHL-1. More sensitive and accurate instruments such as brain imaging (such as brain MRI), brain function (such as NIRS, aEEG), and long-term neuroassay should be used in the future to confirm biomarkers of neonatal brain damage.


Author(s):  
Ahmet Guzelcicek ◽  
Ataman Gönel ◽  
Ismail Koyuncu ◽  
Gulyara Cigdem ◽  
Dogan Kose ◽  
...  

Background:: Hydrocephalus, a common brain disorder in children, can cause permanent brain damage. A timely diagnosis of this disorder is crucial. Objective: The aim of this study was to evaluate the levels of S-100, CK-18, and NSE brain-specific proteins in patients with hydrocephalus. We examined the levels of these proteins in the blood samples of hydrocephalic patients. Methods: The study was conducted on the hydrocephalus (n = 31) patients and a healthy control group (n = 30). A Receiver Operating Characteristic (ROC) curve was used to assess the validity of the NSE, CK-18, and S100B to differentiate between the hydrocephalus and the control groups. The suitability of the data to the normal distribution was tested with the Shapiro Wilk test, and the Student t-test was used to compare the characteristics of the normal distribution in two independent groups. The individuals in the hydrocephalus and control groups had similar values in terms of age, height, and weight. Results: It was observed that NSE, CK-18, and S100B mean values of the individuals in the hydrocephalus group were significantly higher than NSE, CK-18, and S100B mean values of the control group. Conclusion: Experiments have shown that the levels of these proteins increase significantly in hydrocephalus patients compared to the healthy group. These three parameters can be considered as important markers in the diagnosis of hydrocephalus.


2020 ◽  
Vol 1739 ◽  
pp. 146861 ◽  
Author(s):  
Grant C. O'Connell ◽  
Megan L. Alder ◽  
Christine G. Smothers ◽  
Carolyn H. Still ◽  
Allison R. Webel ◽  
...  

2020 ◽  
Vol 42 (4) ◽  
pp. 346-353 ◽  
Author(s):  
Grant C. O’Connell ◽  
Megan L. Alder ◽  
Christine G. Smothers ◽  
Carolyn H. Still ◽  
Allison R. Webel ◽  
...  

2013 ◽  
Vol 23 (1) ◽  
pp. 133-137 ◽  
Author(s):  
Ilona Šuškevičienė ◽  
Milda Nekrašienė ◽  
Danguolė Rugytė ◽  
Alina Vilkė ◽  
Tomas Bukauskas ◽  
...  

In these latter decades neurotoxicity of general anaesthetics has been demonstrated in neonatal animal models. These data raised a concern about the safety of neonatal and paediatric anaesthesia. However, prospective epidemiological studies in humans are still ongoing. Biological markers, which could be associated with anaesthesia and outcome would be helpful in timely decisions regarding clinical practice in newborns and infants. To date, some brain specific proteins have been studies in various brain damage scenarios in neonates, children and adults. The purpose of the present paper is to describe current knowledge, based on experimental and clinical data, on the influence of anaesthetics on the developing brain and the applicability of certain biomarkers in cases of cerebral cell damage.


2011 ◽  
Vol 7 ◽  
pp. S290-S290
Author(s):  
Marcel Verbeek ◽  
Rianne Esselink ◽  
Jurgen Claassen ◽  
Farid Abdo ◽  
Bas Bloem ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2579-2579
Author(s):  
Lisa M. Williams ◽  
Zongming Fu ◽  
Pratima Dulloor ◽  
William J Savage ◽  
Emily Barron-Casella ◽  
...  

Abstract Abstract 2579 Poster Board II-556 Silent cerebral infarction (SCI) is part of a spectrum of cerebrovascular disease, occurs in approximately 22% of children with sickle cell disease (SCD) and is associated with decreased cognitive function. While several plasma biomarkers have been shown to be elevated in acute stroke, to our knowledge none have been evaluated in SCD or SCI. The aim of this study was to develop a reliable pipeline to identify low abundance plasma proteins that correlate with SCI in patients with SCD. We used a proteomic discovery approach involving three sequential separation steps in order to compare the plasma proteomes in a discovery set of 15 children with SCD (7 children with SCI and 8 children without SCI). Baseline steady state plasma samples obtained from the Silent Infarct Transfusion (SIT) Trial Biologic Repository were matched for age and WBC. In the first dimension, hemoglobin was depleted with nickel-nitrilotriacetic acid (Ni-NTA). Subsequently, second dimension separation and enrichment was achieved by immunoaffinity depletion of the 12 most abundant proteins (ProteomeLab IgY-12 LC10) followed by third dimension separation by reverse phase liquid chromatography fractionation (RPLC) using a C18 column and a linear acetonitrile gradient. Collected fractions were subjected to tryptic digestion and analyzed using label-free quantification on a LTQ-Orbitrap (Thermo) mass spectrometer. The MS/MS data were analyzed using the Proteomics Analyzer Software System (PASS) version 4.0.10 (Integrated Analysis Inc, Bethesda, MD) with X! Tandem searches (www.thegpm.org; version 2008.12.01) using the human IPI database. Identified proteins were compared to databases of brain specific and brain enriched proteins to identify candidate biomarker proteins for SCI. After hemoglobin depletion, 71% of total protein was removed. On average, protein recovery after the LC-12 column was 4% of the total Ni-NTA depleted protein. Of the 9800 proteins that were identified in the plasma proteome of children with SCD, 23 were brain specific proteins. Evaluation of the relative abundance by spectral counts (SC) revealed 3 brain-related proteins that were over-represented in patients with SCI: microtubule-associated protein tau (a neurofibrillary tangle protein implicated in Alzheimer disease, frontotemporal dementia and parkinsonism), neuroligin-3 (a neuronal cell surface protein proposed to be involved in cell-cell-interactions via binding to beta-neurexins and implicated in autism and Asperger syndrome), and nucleosome-remodeling factor subunit BPTF (a histone-binding component of nucleosome-remodeling factor that is abundantly expressed in the fetal brain and re-expressed in neurodegenerative diseases). Reticulon-4, a potent neurite growth inhibitor involved in the restriction of axonal regeneration after injury, was under-represented in patients with SCI. After depletion of hemoglobin and other high abundant proteins, we were able to develop a database of plasma proteins in children with SCD and to identify brain specific proteins as potential surrogate markers of brain injury. These markers may be implicated in the pathophysiology of SCI. Although validation studies are necessary to determine the relevance of these candidate biomarkers in SCI and SCD, our methodology appears to be a practical approach to proteomic discovery in patients with hemolytic anemia. Disclosures: Casella: Boehringer Ingelheim: Honoraria, Research Funding, Travel funding.


Sign in / Sign up

Export Citation Format

Share Document